There's pharma companies worth over a billion dollars based on studies with a smaller sample sizes so I don't see N=36 as a deal breaker especially when there's

There's pharma companies worth over a billion dollars based on studies with a smaller sample sizes so I don't see N=36 as a deal breaker especially when there's very little money incentive here.